Using bell and pad alarm therapy is a typical therapy for enuresis in children, a study examines its efficacy in those with neurodevelopmental disorders.
Bell and pad alarm therapy should be used as firstline treatment for children with neurodevelopmental disorders (NDDs) and enuresis, according to study findings. Investigators compared retrospective medical record data for almost 3000 children in Australia who were given an enuresis diagnosis with data for typically developing children. Children with an NDD had a clinical diagnosis of attention-deficit/hyperactivity disorder, autism spectrum disorder, or intellectual disability (ID). Treatment success was defined as remaining dry for at least 14 consecutive days and relapse as 1 symptom recurrence per month after treatment was interrupted.
The investigators found that the bell and pad alarm was nearly as effective in children with NDDs as in typically developing children. For children with NDD, the success rate was 62%; for typically developing children the rate was 78%. The latter all were successfully dry after the first treatment. Only 59% of children with ID had success after the first treatment, the lowest percentage of all groups analyzed. The number of treatments received, or relapse rates, did not differ significantly between the 2 groups. The results also indicated that a child with a NDD and enuresis is more likely than their peers to be male, be older, and have current constipation aligned with a secondary enuresis diagnosis.
Thoughts from Dr. Farber
I was taught that using an alarm system required a cognitive age of at least 6 years. Unfortunately, this study does not give cognitive ages; perhaps the failures in children with NDD reflect cognitive ages below this level, but there is enough here to warrant a trial in such children if the family is interested.
Reference
1. Schuster S, Reece J, Florentzou, Apos E. Treating enuresis in children with neurodevelopmental disorders using bell and pad alarm. J Pediatr Urol. Published online July 21, 2021. doi:10.1016/j.jpurol.2021.07.010
Paternal depression associated with adverse childhood experiences in children
October 21st 2023In this Q&A, Kristine H. Schmitz, MD, explains her team's recent research on paternal depression and adverse childhood experiences during the 2023 American Academy of Pediatrics National Conference & Exhibition.
Exome sequencing should be used for diagnosing cerebral palsy
October 13th 2023A systematic review and meta-analysis found that such sequencing indeed has an equivalent high genetic diagnostic yield in cerebral palsy, which supports including this neurodevelopmental disorder among those for which diagnostic exome sequencing should be used.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.